DiaphOne Therapeutics

Principal Investigators: Ann Marie Schmidt, MD

DiaphOne Therapeutics is developing first-in-class small molecules to treat diabetic nephropathy and other diabetic complications, with potential for additional indications like ALS, Alzheimer’s Disease, and breast cancer. Currently, there are no curative treatments for diabetic nephropathy or other diabetic complications. The approved marketed medications only address secondary disease pathways and not the diseased organ. DiaphOne’s small molecules specifically target the pathophysiology of diabetic complications at their root, without affecting peripheral mechanisms.